{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:01:12Z","timestamp":1795129272525,"version":"4.10.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113313","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T11:20:17Z","timestamp":1693048817000},"page":"113313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-118X","authenticated-orcid":false,"given":"Emily","family":"Alouani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-7044","authenticated-orcid":false,"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madonna","family":"Sakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-4941","authenticated-orcid":false,"given":"Sabine","family":"Messayke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Xavier","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaissa","family":"Ouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113313_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","author":"Wang","year":"2017","journal-title":"Front Pharmacol [Internet]"},{"key":"10.1016\/j.ejca.2023.113313_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113313_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"issue":"4","key":"10.1016\/j.ejca.2023.113313_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2018.06.012","article-title":"Mortality due to immunotherapy related hepatitis","volume":"69","author":"Bhave","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113313_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2023.113313_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2023.113313_bib7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"Martin","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113313_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000486679","article-title":"Risk of liver toxicity with nivolumab immunotherapy in cancer patients","volume":"94","author":"Zarrabi","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2023.113313_bib9","doi-asserted-by":"crossref","unstructured":"Martin ED, Michot JM, Rosmorduc O, Guettier C, Samuel D.Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep [Internet]. 2020 Dec 1 [cited 2023 Apr 14];2(6). Available from: \u3008https:\/\/www.jhep-reports.eu\/article\/S2589\u20135559(20)30104-X\/fulltext\u3009.","DOI":"10.1016\/j.jhepr.2020.100170"},{"issue":"2","key":"10.1016\/j.ejca.2023.113313_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/25785826.2020.1788229","article-title":"Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma","volume":"44","author":"Kubo","year":"2021","journal-title":"Immunol Med"},{"key":"10.1016\/j.ejca.2023.113313_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2019.09.022","article-title":"Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors","volume":"123","author":"Vozy","year":"2019","journal-title":"Eur J Cancer"},{"issue":"36","key":"10.1016\/j.ejca.2023.113313_bib12","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol Off J Am Soc\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.113313_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol Off J Eur Soc\u00a0Med Oncol"},{"issue":"158","key":"10.1016\/j.ejca.2023.113313_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry","volume":"1990","author":"Ruste","year":"2021","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"130","key":"10.1016\/j.ejca.2023.113313_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"1990","author":"Michot","year":"2020","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"11","key":"10.1016\/j.ejca.2023.113313_bib16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"issue":"21","key":"10.1016\/j.ejca.2023.113313_bib17","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.113313_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101619","article-title":"The current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity","volume":"28","author":"Xing","year":"2023","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113313_bib19","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"issue":"12","key":"10.1016\/j.ejca.2023.113313_bib20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113313_bib21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113313_bib22","article-title":"Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: a report of two cases and literature review","volume":"5","author":"Ueno","year":"2022","journal-title":"Cancer Rep"},{"issue":"3","key":"10.1016\/j.ejca.2023.113313_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.113313_bib24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Wouters MWJM, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, et al. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.ejca.2023.113313_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.32215","article-title":"Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis","volume":"75","author":"Li","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2023.113313_bib26","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.ejca.2023.113313_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jgh3.12868","article-title":"Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: a retrospective study","volume":"7","author":"Kadokawa","year":"2023","journal-title":"JGH Open"},{"issue":"9","key":"10.1016\/j.ejca.2023.113313_bib28","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2023.113313_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113313_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/10781552221103548","article-title":"Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series","volume":"29","author":"Tew","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2023.113313_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208102","article-title":"Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","volume":"2015","author":"Ahmed","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.ejca.2023.113313_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113313_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1684\/ejd.2017.2973","article-title":"Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events","volume":"27","author":"Iwamoto","year":"2017","journal-title":"Eur J Dermatol EJD"},{"key":"10.1016\/j.ejca.2023.113313_bib34","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2023-0085","article-title":"Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature","author":"Ali","year":"2023","journal-title":"Immunotherapy [Internet]"},{"issue":"12","key":"10.1016\/j.ejca.2023.113313_bib35","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am J Transplant"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300415X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300415X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:55Z","timestamp":1760733775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300415X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S095980492300415X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113313","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113313"}}